Varenicline - Increased cardiovascular risk in smoking cessation?

被引：0
作者：
Dewenter, M. [1 ]
El-Armouche, A. [1 ]
机构：
[1] Universitatsmed Gottingen, Abt Pharmakol, Robert Koch Str 40, D-37075 Gottingen, Germany
来源：
KARDIOLOGE | 2012年 / 6卷 / 03期
关键词：
Nicotine dependence; Varenicline; Nicotine receptor partial agonist; Smoking cessation; Cardiovascular risknur;
D O I：
10.1007/s12181-012-0425-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Smoking is one of the most important cardiovascular risk factors. Varenicline, a partial agonist of the alpha(4)beta(2) nicotinic acetylcholine receptor, has been demonstrated to be the most efficacious medication for smoking cessation. However, treatment with varenicline has sometimes been associated with severe cardiovascular side effects. This article discusses the current data with respect to the cardiovascular safety of varenicline therapy.
引用
收藏
页码：240 / 243
页数：4
相关论文
共 26 条
  • [1] Alper BS, 2011, CAN MED ASSOC J, V183, P1405, DOI 10.1503/cmaj.111-2071
  • [2] Centers for Disease Control and Prevention, 2010, TOBACCO SMOKE CAUSES
  • [3] Optimal risk factor modification and medical management of the patient with peripheral arterial disease
    Chi, Yung-Wei
    Jaff, Michael R.
    [J]. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2008, 71 (04) : 475 - 489
  • [4] Association of Diet, Exercise, and Smoking Modification With Risk of Early Cardiovascular Events After Acute Coronary Syndromes
    Chow, Clara K.
    Jolly, Sanjit
    Rao-Melacini, Purnima
    Fox, Keith A. A.
    Anand, Sonia S.
    Yusuf, Salim
    [J]. CIRCULATION, 2010, 121 (06) : 750 - 758
  • [5] Varenicline:: An α4β2 nicotinic receptor partial agonist for smoking cessation
    Coe, JW
    Brooks, PR
    Vetelino, MG
    Wirtz, MC
    Arnold, EP
    Huang, JH
    Sands, SB
    Davis, TI
    Lebel, LA
    Fox, CB
    Shrikhande, A
    Heym, JH
    Schaeffer, E
    Rollema, H
    Lu, Y
    Mansbach, RS
    Chambers, LK
    Rovetti, CC
    Schulz, DW
    Tingley, FD
    O'Neill, BT
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (10) : 3474 - 3477
  • [6] Mortality risk reduction associated with smoking cessation in patients with coronary heart disease - A systematic review
    Critchley, JA
    Capewell, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (01): : 86 - 97
  • [7] Critchley JA, 2012, COCHRANE DB SYST REV, V2, pCD003041
  • [8] Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system
    Dani, John A.
    Bertrand, Daniel
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2007, 47 : 699 - 729
  • [9] FDA Drug Safety Newsletter, 2009, POSTMARKET REV, V2, P1
  • [10] Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation -: A randomized controlled trial
    Gonzales, David
    Rennard, Stephen I.
    Nides, Mitchell
    Oncken, Cheryl
    Azoulay, Salomon
    Billing, Clare B.
    Watsky, Eric J.
    Gong, Jason
    Williams, Kathryn E.
    Reeves, Karen R.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (01): : 47 - 55
123